Therapeutic effects of vitamin D3 in women with recurrent spontaneous abortion

Study of the effect of 1.25 Dihydroxy-vitamin D3 on the Th17/Treg (Cd4, FoxP3) ratio in the women with recurrent spontaneous abortion with vitamin D3 deficiency candidate for lymphocyte therapy

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT201201258820N1

Enrollment

Registered

2012-03-12

Start date

2012-04-20

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

recurrent spontaneous abortion with immunology reasons. pregnancy with abortive outcome

Interventions

Intervention 1: Intervention group: injection of vitamin D3, 300000 IU, one injection. Intervention 2: Control group: injection plasebo containing solvent material of vitamin D3, one injection.

Treatment - Drugs

Placebo

Intervention group: injection of vitamin D3, 300000 IU, one injection

Control group: injection plasebo containing solvent material of vitamin D3, one injection

Eligibility

Sex/Gender

Female

Age

20 Years to 45 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: 1) women with RSA in age 20-45 years with possibility of immunology reasons candidate for lymphocyte therapy; 2) the women with RSA who have serum levels of vitamin D3 less than or equal 100 nmol/l; 3) having a regular menstrual cycle. Exclusion criteria: 1) having an irrigular menstrual cycle 2) women who have consumed vitamin D3 in three months ago.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Treg. Timepoint: before intervention and 3 months of iintervention. Method of measurement: with flow cytometry by detect CD4 and FoxP3 markers.;TH17. Timepoint: before intervention 3 months of intervention. Method of measurement: with flow cytometry by detect CD4 and IL17 markers.;TH17 to Treg ratio. Timepoint: before intervention and 3 months of intervention. Method of measurement: with dividing of TH17 to Treg.;The levels of vitamin D. Timepoint: before and after intervention. Method of measurement: Elisa.	—

Measure

Time frame

Treg. Timepoint: before intervention and 3 months of iintervention. Method of measurement: with flow cytometry by detect CD4 and FoxP3 markers.;TH17. Timepoint: before intervention 3 months of intervention. Method of measurement: with flow cytometry by detect CD4 and IL17 markers.;TH17 to Treg ratio. Timepoint: before intervention and 3 months of intervention. Method of measurement: with dividing of TH17 to Treg.;The levels of vitamin D. Timepoint: before and after intervention. Method of measurement: Elisa.

—

Secondary

Measure	Time frame
Pregnancy outcome. Timepoint: from 3 months after the end of treatment. Method of measurement: infant birth.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMitra Rafiee

Isfahan university of medical sciences

mitra_rafiee@yahoo.com+98 56 1444 7331

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026